Compare Adaptive Biotechnologies Corp (ADPT) vs Harmony Gold Mining Co. (HMY) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Harmony Gold Mining Co. — how do they compare? Adaptive Biotechnologies Corp trades at $19.87 (market cap $3.33B), while Harmony Gold Mining Co. trades at $14.4 (market cap $9.60B). The key difference: Harmony Gold Mining Co. is far larger — about 2.9× Adaptive Biotechnologies Corp's market cap, and Harmony Gold Mining Co. pays a 2.65% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | HMY | |
|---|---|---|
Market Cap | $3.33B | $9.60B |
Sector | Health | Basic Materials |
52-Week High | $22.37 | $26.04 |
52-Week Low | $10.24 | $12.61 |
Enterprise Value | $3.19B | $9.93B |
Dividend Yield | — | 2.65% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
Harmony Gold Mining (HMY) trades at $15.385, down 4.38% amid broader gold sector weakness. The stock shows strong fundamentals with 2024 revenue of $61.38B and net income of $8.59B, representing a 13.99% margin. Technical indicators signal bearish momentum with RSI at oversold levels. Recent earnings beat expectations in Q2 2025 but missed in Q4 2025, while analysts maintain a cautious stance with 70% hold ratings.
HMY presents value with attractive valuation ratios (P/E 10.42, EV/EBITDA 5.36) and robust profitability (ROE 32.32%). However, Fed rate hike concerns and gold price volatility pose near-term headwinds. The company's transition to gold-copper hybrid operations by 2028 offers long-term growth potential, though execution risks and commodity price exposure remain key considerations for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Harmony Gold Mining Co.
Harmony Gold Mining Co Ltd is a gold mining and exploration company having operations in South Africa and Papua New Guinea (PNG). Its projects include Bambanani, Joel, Masimong, Phakisa, Target 1, Tshepong, Unisel, Doornkop, and Kusasalethu. The group's segments are Tshepong Operations, Bambanani, Joel, Doornkop, Moab Khotsong, Hidden Valley, Target 1, Kusasalethu, Masimong, Unisel, and all other surface operations.
Read more on HMY →
